↓ Skip to main content

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer

Overview of attention for article published in Journal of Translational Medicine, March 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#9 of 3,826)
  • High Attention Score compared to outputs of the same age (99th percentile)

Mentioned by

news
71 news outlets
twitter
13 tweeters
patent
6 patents

Citations

dimensions_citation
190 Dimensions

Readers on

mendeley
223 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Published in
Journal of Translational Medicine, March 2015
DOI 10.1186/s12967-015-0460-x
Pubmed ID
Authors

Mythili Koneru, Roisin O’Cearbhaill, Swati Pendharkar, David R Spriggs, Renier J Brentjens

Abstract

Recurrent platinum-resistant ovarian cancer has no curative options, necessitating the development of novel treatments, including immunotherapy. Patient-derived T cells can be genetically modified to express chimeric antigen receptors (CARs) specific to tumor-associated antigens in an HLA-independent manner, with promising preclinical results. MUC16(ecto) is highly expressed on most epithelial ovarian carcinomas but at low levels on normal tissues, offering an excellent immunotherapeutic target for this cancer. CAR T cells further modified to secrete IL-12 show enhanced cytotoxicity, persistence, and modulation of the tumor microenvironment. We propose a dose escalation phase I clinical trial for patients with recurrent MUC-16(ecto+) ovarian cancer to test the safety of intravenous and intraperitoneal administration and the preliminary efficacy of autologous IL-12 secreting, MUC-16(ecto) CAR T cells containing a safety elimination gene. This trial targets MUC-16(ecto), a novel and promising tumor-associated antigen. This will be the first time CAR T cells are injected intraperitoneally directly into the site of the tumor within the abdomen in humans. Furthermore, the ability of genetically modified cells to secrete IL-12 will potentially enhance CAR T cell persistence and modulate the tumor microenvironment. For safety purposes, an elimination gene has been incorporated into the CAR T cells to mitigate any on-target, off-tumor or other unforeseen toxicity.

Twitter Demographics

The data shown below were collected from the profiles of 13 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 223 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 2%
Portugal 1 <1%
Canada 1 <1%
Unknown 217 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 47 21%
Student > Ph. D. Student 32 14%
Student > Bachelor 30 13%
Student > Master 26 12%
Other 10 4%
Other 32 14%
Unknown 46 21%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 42 19%
Medicine and Dentistry 40 18%
Immunology and Microbiology 30 13%
Agricultural and Biological Sciences 28 13%
Pharmacology, Toxicology and Pharmaceutical Science 9 4%
Other 21 9%
Unknown 53 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 567. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 August 2022.
All research outputs
#31,833
of 22,077,419 outputs
Outputs from Journal of Translational Medicine
#9
of 3,826 outputs
Outputs of similar age
#326
of 241,002 outputs
Outputs of similar age from Journal of Translational Medicine
#1
of 1 outputs
Altmetric has tracked 22,077,419 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,826 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,002 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them